A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.
A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.
Preliminary research studies have shown that patients with Hodgkin lymphoma may overexpress the programmed death ligand-1 (PD-1) protein on their cell surface, indicating that the tumors may be dependent on PD-1 for survival, and thus making it an ideal drug target. To test this hypothesis, the KEYNOTE-013 trial enrolled 31 patients with relapsed, refractory Hodgkin lymphoma who had progressed following treatment with brentuximab vedotin. Patients were treated with pembrolizumab every 2 weeks until week 12, and every 8 weeks after, until disease progression. Safety and complete remission (CR) rate were the primary trial endpoints.
Of the 31 patients, 55% had had more than 4 lines of therapy and 71% had relapsed following autologous stem cell transplant. The observed CR rate was 16% (90% CI, 7% to 31%). Nearly half (48%) the patients achieved a partial remission for an overall response rate of 65% (90% CI, 48% to 79%). A majority (70%) of the responses lasted for more than 6 months, with a median follow-up of 17 months.
The most commonly observed adverse events (AEs) were hypothyroidism (16%), diarrhea (16%), nausea (13%), and pneumonitis (10%). Grade 3 AEs were observed in 16% of patients, namely colitis, increased ALT and AST levels, nephrotic syndrome, joint swelling, back pain, and axillary pain. There were no grade 4 treatment-related AEs.
The authors feel that their results are a sufficient prerogative for further studies of pembrolizumab in patients with Hodgkin lymphoma.
The study is published in the November issue of the Journal of Clinical Oncology.
Preventative Chemotherapy? Not Quite, but Studies Are Underway in Immunoprevention
March 23rd 2024The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors
March 15th 2024The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.
Read More